Evolva
Provides products that can contribute to health, wellbeing and sensory enjoyment.
Launch date
Employees
Market cap
€5.2m
Enterprise valuation
€15m (Public information from Sep 2024)
Share price
CHF0.91 EVE.SW
Company register number CH-170.3.027.314-6
Reinach Canton of Basel-Landschaft (HQ)
Financials
Estimates*
| CHF | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 11.6m | 7.5m | 9.9m | 15.5m | 23.4m | 45.8m | 67.6m |
| % growth | 45 % | (35 %) | 31 % | 57 % | 50 % | 96 % | 48 % |
| EBITDA | (16.1m) | (20.8m) | (31.9m) | (35.3m) | - | - | - |
| % EBITDA margin | (139 %) | (276 %) | (322 %) | (227 %) | - | - | - |
| Profit | (21.6m) | (29.9m) | (41.3m) | (43.4m) | - | - | - |
| % profit margin | (187 %) | (396 %) | (418 %) | (279 %) | - | - | - |
| R&D budget | 13.7m | 13.6m | 22.4m | 23.6m | - | - | - |
| R&D % of revenue | 118 % | 180 % | 227 % | 152 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$14.8m | Series A | ||
| N/A | N/A | IPO | |
$10.3m | Series A | ||
$5.0m | Grant | ||
$27.5m | Post IPO Equity | ||
N/A | Grant | ||
CHF12.0m | Post IPO Equity | ||
CHF12.0m | Post IPO Debt | ||
* | N/A | CHF6.3m | Post IPO Equity |
* | $540k | Grant | |
* | CHF12.0m | Post IPO Convertible | |
* | $23.5m Valuation: $23.5m | Acquisition | |
| Total Funding | €27.8m | ||
